Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors

Journal of Medicinal Chemistry

Volumn 43, Issue 15, 2000, Pages 2860-2870

  Kalgutkar, Amit S ^a   Marnett, Alan B ^a   Crews, Brenda C ^a   Remmel, Rory P ^a,b   Marnett, Lawrence J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,8,11,14 ICOSATETRAYNOIC ACID; ACETYLSALICYLIC ACID; AMIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTER DERIVATIVE; FLURBIPROFEN; INDOMETACIN; INDOMETACIN DERIVATIVE; MECLOFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ZOMEPIRAC;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DERIVATIZATION; DRUG POTENCY; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; INHIBITION KINETICS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INDOMETHACIN; ISOENZYMES; MACROPHAGES; MEMBRANE PROTEINS; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SHEEP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034721194     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000004e     Document Type: Article

References (45)

1. Hawkey, C. J. COX-2 Inhibitors. Lancet 1999, 353, 307-314.
2. DeWitt, D. L.; Smith, W. L. Primary Structure of Prostaglandin G/H Synthase From Sheep Vesicular Gland Determined from the Complementary DNA Sequence. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 1412-1416.
3. Yokoyama, C.; Tanabe, T. Cloning of Human Gene Encoding Prostaglandin Endoperoxide Synthase and Primary Structure of the Enzyme. Biochem. Biophys. Res. Commun. 1989, 165, 888-894.
4. Hla, T.; Neilson, K. Human Cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384-7388.
5. Allison, M. C.; Howatson, A. G.; Torrence, C. J.; Lee, F. D.; Russel, R. I. Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1992, 327, 749-754.
6. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, A Phorbol Ester Tumor Promoter Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-12872.
7. Lee, S. H.; Soyoola, E.; Chanmugam, P.; Hart, S.; Sun, W.; Zhong, H.; Liou, S.; Simmons, D.; Hwang, D. Selective Expression of Mitogen-Inducible Cyclooxygenase in Macrophages Stimulated with Lipopolysaccharide. J. Biol. Chem. 1992, 267, 25934-25938.
8. O'Sullivan, M. G.; Huggins, E. M., Jr.; Mccall, C. E. Lipopolysaccharide-Induced Expression of Prostaglandin H Synthase-2 in Aveolar Macrophages is Inhibited by Dexamethasone but not by Aspirin. Biochem. Biophys. Res. Commun. 1993, 191, 1294-1300.
9. Smith, C. J.; Zhang, Y.; Koboldt, C. M.; Muhammad, J.; Zweifel, B. S.; Shaffer, A.; Talley, J. J.; Masferrer, J. L.; Seibert, K.; Isakson, P. C. Pharmacological Analysis of Cyclooxygenase-1 in Inflammation. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13313-13318.
10. Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase-2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232.
11. Vane, J. R.; Mitchell, J. A.; Appleton, I.; Tomlinson, A.; Bishop-Bailey, D.; Croxtall, J.; Willoughby, D. A. Inducible Isoforms of Cyclooxygenase and Nitric Oxide Synthase in Inflammation. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2046-2050.
12. Harada, Y.; Hatanaka, K.; Saito, M.; Majima, M.; Ogino, M.; Kawamura, M.; Ohno, T.; Yang, Q.; Katori, M.; Yamamoto, S. Detection of Inducible Prostaglandin H Synthase-2 in Cells in the Exudate of Rat Carrageenin-Induced Pleurisy. Biomed. Res. 1994, 15, 127-130.
13. Warner, T. D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.; Vane, J. R. Nonsteroid Drug Selectivities for Cyclo-oxygenase-1 Rather than Cyclo-oxygenase-2 are Associated with Human Gastrointestinal Toxicity: A Full In Vitro Analysis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7563-7568.
14. Simon, L. S.; Lanza, F. L.; Lipsky, P. E.; Hubbard, R. C.; Talwalker, S.; Schwartz, B. D.; Isakson, P. C.; Geis, G. S. Preliminary Study of the Safety and Eficacy of SC-58635, a Novel Cyclooxygenase-2 Inhibitor: Efficacy and Safety in Two Placebo-Controlled Trials in Osteoarthritis and Rheumatoid Arthritis, and Studies of Gastrointestinal and Platelet Effects. Arthritis Rheumatism 1998, 41, 1591-1602.
15. Ehrich, E. W.; Dallob, A.; De Lepeleire, I.; Van Hecken, A.; Riendeau, D.; Yuan, W.; Porras, A.; Wittreich, J.; Seibold, J. R.; De Schepper, P.; Mehlisch, D. R.; Gertz, B. J. Characterization of Rofecoxib as a Cyclooxygenase-2 Isoform Inhibitor and Demonstration of Analgesia in the Dental Pain Model. Clin. Pharmacol. Ther. 1999, 65, 336-347.
16. Kalgutkar, A. S. Selective Cyclooxygenase-2 Inhibitors as Non-Ulcerogenic Antiinflammatory Agents. Exp. Opin. Ther. Patents 1999, 9, 831-849.
17. Marnett, L. J.; Kalgutkar, A. S. Cyclooxygenase-2 Inhibitors: Discovery, Selectivity and the Future. Trends Pharmacol. Sci. 1999, 20, 465-469.
18. Talley, J. J. Selective Inhibitors of Cyclooxygenase-2. Exp. Opin. Ther. Patents 1997, 7, 55-62.
19. Carter, J. S. Recently Reported Inhibitors of Cyclooxygenase-2. Exp. Opin. Ther. Patents 1997, 8, 21-29.
20. Prasit, P.; Riendeau, D. Selective Cyclooxygenase-2 Inhibitors. In Annual Reports in Medicinal Chemistry; Hagmann, W. K., Ed.; Academic Press Inc.; New York, 1997; Vol 32, pp 211-220.
21. (a) Black, W. C.; Bayly, C.; Belley, M.; Chan, C.-C.; Charleson, S.; Denis, D.; Gauthier, J. Y.; Gordon, R.; Guay, D.; Kargman, S.; Lau, C. K.; Leblanc, Y.; Mancini, J.; Quellet, M.; Percival, D.; Roy, P.; Skorey, K.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P. From Indomethacin to a Selective COX-2 Inhibitor: Development of Indolalkanoic Acids as Potent and Selective Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 725-730.
22. (b) LeBlanc, Y.; Black, W. C.; Chan, C.-C.; Charleson, S.; Delorme, D.; Denis, D.; Gauthier, J. Y.; Gordon, R.; Guay, D.; Hamel, P.; Kargman, S.; Lau, C. K.; Mancini, J.; Quellet, M.; Percival, D.; Roy, P.; Skorey, K.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P. Synthesis and Biological Evaluation of Both Enantiomers of L-761,000 as Inhibitors of Cyclooxygenase-1 and 2. Bioorg. Med. Chem. Lett. 1996, 6, 731-736.
23. (a) Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933.
24. 2 synthase-1. Nature 1994, 367, 243-249.
25. (a) Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W.; Garner, C.; Seibert, K.; Marnett, L. J. Aspirin-Like Molecules that Covalently Inactivate Cyclooxygenase-2. Science 1998, 280, 1268-1270.
26. (b) Kalgutkar, A. S.; Kozak, K. R.; Crews, B. C.; Hochgesang, Jr., G. P.; Marnett, L. J. Covalent Modification of Cyclooxygenase-2 (COX-2) by 2-(Acetoxyphenyl)alkyl Sulfides, a New Class of Selective COX-2 Inactivators. J. Med. Chem. 1998, 41, 4800-4818.
27. Bayly, C. I.; Black, W. C.; Leger, S.; Quimet, N.; Quellet, M.; Percival, M. D. Structure-Based Design of COX-2 Selectivity Into Flurbiprofen. Bioorg. Med. Chem. Lett. 1999, 9, 307-312.
28. Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W.; Marnett, A. B.; Kozak, K. R.; Remmel, R. P.; Marnett, L. J. Biochemically Based Design of Cyclooxygenase (COX-2) Inhibitors. Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective COX-2 Inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 925-930.
29. 2 is a mediator of Cyclooxygenase-2-Dependent Endothelial Migration and Angiogenesis. Cancer Res. 1999, 59, 9, 4574-4577.
30. Diago-Meseguer, J.; Palomo-Coll, A. L.; Fernandez-Lizarbe, J. R.; Zugaza-Bilbao, A. A New Reagent for Activating Carboxyl Groups; Preparation and Reactions of N,N-Bis[2-oxo-3-oxazolidinyl]phosphorodiamidic Chloride. Synthesis 1980, 547-551.
31. Wang, W.; McMurray, J. S. A Selective Method for the Preparation of Primary Amides: Synthesis of Fmoc-L-4-Carboxamidophenylalanine and Other Compounds. Tetrahedron Lett. 1999, 40, 2501-2504.
32. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, A Novel Nonsteroidal Antiinflammatory Drug With Potent Analgesic and Antipyretic Effects, Which Causes Minimal Stomach Lesions. Gen. Pharmacol. 1993, 24, 105-110.
33. Talley, J. J.; Bertenshaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Norman, B. H.; Rogier, Jr., D. J.; Zweifel, B. S.; Seibert, K. 4,5-Diaryloxazole Inhibitors of Cyclooxygenase-2 (COX-2). Med. Res. Rev. 1999, 19, 199-208.
34. Shen, T. Y. Antiinflammatory Amides. U.S. Patent 3,285,908, 1966.
35. Flynn, D. L.; Capiris, T.; Cetenko, W. J.; Connor, D. T.; Dyer, R. D.; Kostlan, C. R.; Nies, D. E.; Schrier, D. J.; Sircar, J. C. Nonsteroidal Antiinflammatory Drug Hydroxamic Acids. Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase. J. Med. Chem. 1990, 33, 2070-2072.
36. (a) Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Antiinflammatory Agents. Nature 1996, 384, 644-648.
37. (b) Gierse, J. K.; McDonald, J. J.; Hauser, S. D.; Rangwala, S. H.; Koboldt, C. M.; Seibert, K. A Single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2-Specific Inhibitors. J. Biol. Chem. 1996, 271, 15810-15814.
38. (c) Wong, E.; Bayly, C.; Waterman, H. L.; Riendeau, D.; Mancini, J. A. Conversion of Prostaglandin G/H Synthase-1 Into an Enzyme Sensitive to PGHS-2-Selective Inhibitors by a Double His513Arg and Ile523Val Mutation. J. Biol. Chem. 1997, 272, 9280-9286.
39. (d) Guo, Q.; Wang, L.-H.; Ruan, K.-H.; Kulmacz, R. J. Role of Val509 in Time-Dependent Inhibition of Prostaglandin H Synthase-2 Cyclooxygenase Activity by Isoform-Selective Agents. J. Biol. Chem. 1996, 271, 19134-19139.
40. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, I. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Nita Cogburn, J.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
41. American Home Products Corp. WO9821195, 1997.
42. Marnett, L. J.; Siedlik, P. H.; Ochs, R. C.; Pagels, W. D.; Das, M.; Honn, K. V.; Warnock, R. H.; Tainer, B. E.; Eling, T. E. Mechanism of the Stimulation ofProstaglandin H Synthase by the Antithrombotic and Antimetastatic Agent, Nafazatrom. Mol. Pharmacol. 1990, 26, 328-335.
43. Odenwaller, R.; Chen, Y.-N. P.; Marnett, L. J. Preparation and Proteolytic Cleavage of Apoprostaglandin Endoperoxide Synthase. Methods Enzymol. 1990, 187, 479-485.
44. Rome, L. H.; Lands, W. E. M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by antiinflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 4863-4865.
45. De Martiis, F.; Franzone, J. S.; Tamietto, T. Synthesis and antiphlogistic properties of some indolylacetohydroxamic acids. Boll. Chim. Farm. 1976, 114, 309-318.